Marksans Pharma Ltd Reports Audited Financial Results for FY 2025-26; Group Revenue Reaches 30,334.71 Million
Marksans Pharma Limited has released its audited standalone and consolidated annual financial results for the fiscal year ended March 31, 2026. The company reported significant growth across its operations, highlighting key achievements in profitability and asset accumulation.The Group operates primarily within the pharmaceutical sector and maintains a single reportable segment defined as 'Pharmaceuticals' per Ind AS 108 on Operating Segments.
Consolidated Financial Performance
For the year ended March 31, 2026, the consolidated financial results show robust performance across various metrics. The Group reported Total Income of 30,334.71 million in FY 2025-26 and achieved a Profit After Tax (PAT) of 4,200.64 million.The company’s total assets stood at 38,609.02 million as of March 31, 2026, compared to 32,396.32 million in the previous fiscal year.
Key figures from the Consolidated Annual Financial Results are presented below:
| Particulars | As at 31 Mar 2026 (AUDITED) (in millions) | As at 31 Mar 2025 (AUDITED) (in millions) |
|---|---|---|
| Total Income | 30,334.71 | 7,237.95 |
| Profit After Tax (PAT) | 4,200.64 | N/A |
| Total Assets | 38,609.02 | 32,396.32 |
Standalone Financial Highlights
Marksans Pharma Ltd's standalone results also reflect a strong year, with revenue from operations reaching 13,414.76 million for the full financial year ended March 31, 2026. The company reported a Profit After Tax of 3,006.98 million for the same period.The standalone balance sheet indicated that Total Assets stood at 19,940.29 million as of March 31, 2026, an increase from 17,553.02 million in March 2025.
Strategic and Governance Updates
In addition to the financial results, the company provided several operational updates regarding governance and expansion during the reporting period:- New Subsidiaries: The Company incorporated two new wholly owned subsidiaries during the quarter ended March 31, 2026: Marksans Pharma (Europe) Limited in Ireland on January 16, 2026, and Marksans (Canada) Inc. in Canada on January 22, 2026.
- Dividend Recommendation: The Board of Directors recommended a final dividend of ~0.90 per equity share of ~1 each for the Financial Year 2025-26.
- Employees Stock Option Scheme (ESOS): The Board and Shareholders approved the Marksans Employees Stock Option Scheme 2024, under which the company granted 400,000 equity stock options of face value of ~1 each to eligible employees on September 24, 2025.
The audited financial results for both the standalone entity and the consolidated group are available on the company's official website and relevant stock exchange platforms.
MARKSANS Stock Price Movement
Marksans Pharma Limited shares slipped on Thursday, settling at ₹256.07 after the stock shed 1.91% of its value. The equity traded for a volume of 1.42 million shares, having ranged intraday between ₹253.6 and ₹265.85.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.